Title	4‐month disease control rate
Number of Patients Screened	28
Number of Patients Enrolled	26
Number of Patients Evaluable for Toxicity	25
Number of Patients Evaluated for Efficacy	25
Evaluation Method	RECIST 1.1
Response Assessment OTHER	n = 8 (32%)
Primary endpoint of 4‐month disease control rate was defined as no more than 19% increase from baseline in tumor volume, and therefore, complete response, partial response, or stable disease, when assessed at 16 weeks